About this trial
To describe the peripheral serum levels of the anti-inflammatory cytokines IL-4 (Interleukin-4), IL-10 (Interleukin-10), TGF-ß1 (Transforming Growth Factor beta1), the pro-inflammatory cytokines IL-17 (Interleukin-17), IFγ (Interferon Gamma) and the immune mediator PIBF (Progesterone-Induced Blocking Factor) along a single frozen euploid blastocyst transfer in a natural cycle (NC) or Hormone Replacement Therapy (HRT).
Eligibility criteria
Qualifiers
Women aged 18 years to 40 years
Having at least one good quality (grade A or B for inner mass cell and trophectoderm) day 5 or 6 chromosomally normal cryopreserved blastocyst available for transfer
Single embryo transfer in a natural cycle (NC) or an Hormone Replacement Therapy (HRT) protocol
Fresh ejaculate used for fertilization
Disqualifiers
Body mass index lower than 18.5 or equal or higher than 29 kg/m2
Endometriosis or adenomyosis suspected by medical history (dysmenorrhea, dyspareunia, heavy or prolonged menstrual bleeding (> 8 days), chronic pelvic pain, catamenial rectal or bladder symptoms) or diagnosed by imaging (magnetic resonance imaging or ultrasonography)
Uterine abnormalities
Hydrosalpinx
Trial design
Treatments tested in this trial
- Endometrin 100Mg Vaginal Insert
- Estradiol Valerate